Skin Cancer Risk Calculator

Use the Skin Cancer Risk Calculator

Free skin cancer risk calculator: score melanoma and basal cell risk from Fitzpatrick skin type, mole count, blistering sunburns, sunbeds and family history.

How to Use Skin Cancer Risk Calculator

1. Step 1: Set your Fitzpatrick skin type

   Pick the Fitzpatrick type that matches how your skin reacts to 30 minutes of midday summer sun after months indoors, then add your natural hair colour at age 20, eye colour and freckling pattern.

2. Step 2: Count your moles

   Choose a whole-body mole band and an atypical mole count. If counting everything is impractical, count one arm: more than 11 moles there usually means over 100 in total.

3. Step 3: Enter your sun and sunbed history

   Record only blistering or peeling sunburns, when you first used a sunbed, your cumulative outdoor exposure, and the latitude where you have lived longest.

4. Step 4: Add age and medical history

   Enter your age, family history of melanoma, any previous skin cancer, and tick the boxes for actinic keratoses or immunosuppression if either applies.

5. Step 5: Read your multiplier and driver

   Your melanoma risk multiplier, estimated lifetime and 20-year risk, and separate basal/squamous cell tier appear instantly, along with the factor group contributing most of your excess risk.

6. Step 6: Act on the screening cadence

   Use the self-exam and clinician intervals shown, then run the ABCDE and ugly-duckling checklist on your moles and copy the summary to take to an appointment.

Key Features

• Separate melanoma and basal/squamous cell (keratinocyte) risk scores
• Mole-count and atypical-naevus multipliers from the Gandini meta-analysis
• Correlation adjustment so overlapping pigmentation traits are not double-counted
• Contribution bar showing which factor group drives your number
• Screening cadence plus an ABCDE and ugly-duckling self-exam checklist

Understanding Results

Formula

Your inputs are sorted into five groups, each collapsed to one multiplier, then combined:

Risk = (Pigmentation × Moles × Intermittent UV × History × Ambient UV)^0.8

• Pigmentation takes the single largest of your Fitzpatrick, hair, eye and freckling multipliers rather than their product, because those four traits read the same underlying MC1R biology and multiplying them triple-counts it.
• Moles multiplies the whole-body count multiplier by the square root of the atypical-mole multiplier, since atypical counts rise with total counts.
• Intermittent UV multiplies blistering sunburns, sunbed use and actinic keratoses. Cumulative outdoor exposure is deliberately excluded here and routed to the basal/squamous cell score instead.
• History multiplies family history, your own prior skin cancers and immunosuppression.
• The 0.8 exponent shrinks the product. Meta-analytic relative risks are each estimated against a general population that already contains the other factors, so an unshrunk product overstates combined risk.

The multiplier is then applied to a reference lifetime risk of 0.85% — an adult with olive skin, dark hair and eyes, fewer than 15 moles and no blistering sunburns. The 20-year figure instead integrates US age-specific melanoma incidence across the two decades ahead of your current age, so a 65-year-old and a 30-year-old with identical phenotypes get different near-term numbers.

Reference Ranges & Interpretation

Multipliers map to four tiers: Low under 2×, Moderate 2 to 4.9×, High5 to 11.9×, and Very Highat 12× or above. A prior melanoma, five or more atypical moles, or active immunosuppression overrides the arithmetic and places you in Very High regardless of the other answers.

A calibration check: enter the profile of a typical fair-skinned adult — Fitzpatrick type II, 15 to 40 moles, one or two lifetime blistering sunburns, no family history — and the estimated lifetime risk lands at 2.5%, or 1 in 39. The American Cancer Society puts lifetime melanoma risk for white Americans at roughly 1 in 38. The basal and squamous cell tier runs on a separate calculation weighted by age, cumulative outdoor exposure and immune status, which is why a 70-year-old outdoor worker can score Low for melanoma and Very High for keratinocyte carcinoma at the same time.

Assumptions & Limitations

The underlying relative risks come from Gandini et al. (2005), whose source cohorts were overwhelmingly of European ancestry. The multipliers for Fitzpatrick types V and VI are extrapolated from incidence data rather than measured directly, so treat them as order-of- magnitude estimates.

Three things this model cannot see. It has no input for acral or mucosal melanoma, which arises on soles, palms, nail beds and mucous membranes largely independently of UV and phenotype — the very melanomas most likely to affect people this tool scores as Low risk. It cannot account for xeroderma pigmentosum or other DNA-repair disorders, which raise risk by orders of magnitude no additive model handles. And self-reported mole counts run low: people routinely underestimate by 20 to 30% when counting their own backs.

This is an educational estimate, not a diagnosis or a screening test. It cannot examine your skin and it cannot rule anything out. A lesion that is changing in size, shape or colour, or one that itches, bleeds or fails to heal, warrants a clinician regardless of the number this page produced.

Complete Guide: Skin Cancer Risk Calculator

A skin cancer risk calculator exists because two people can spend the same fortnight on the same Mediterranean beach and walk away with melanoma risks that differ by a factor of ten. Sun is the input everyone thinks about. It is not the input that separates them. What separates them is how many moles they carry, how their skin answered its first serious burn thirty years ago, and whether a parent ever had a lesion excised. This guide runs two real-shaped profiles through the arithmetic, then explains the parts of the model that most online risk quizzes get wrong.

Two people, one beach: a worked risk tally

Meet Dan and Priya. Both are 45. Both booked the same week in Crete. Dan is a Fitzpatrick type II with light brown hair, blue eyes, and freckles across his shoulders. He has about 70 moles, two of which a GP once called "a bit irregular". He blistered badly on family holidays as a teenager — four or five times that he remembers. His mother had a melanoma removed from her calf at 58. Priya is a Fitzpatrick type IV: olive skin, dark hair, dark eyes, no freckling. She counts maybe a dozen moles, none atypical, and she has never blistered.

Dan lands at 14.6 times the reference risk, which puts his estimated lifetime melanoma risk at 12.4% — about 1 in 8. Priya sits at the reference itself, 0.85%, or 1 in 118. That gap did not open up during their week in Crete. It opened during Dan's adolescence and at conception. His moles alone account for 42% of his excess risk, more than his sunburn history and his family history put together.

This is also the practical payoff of the calculation. Dan cannot un-count 70 moles, but knowing that moles are his dominant term tells him exactly what his surveillance should look like: annual dermoscopy and baseline photographs, not a stricter sunscreen habit. Priya's result tells her the opposite — that a monthly self-check is proportionate and a standing dermatology appointment is not.

Why the outdoor worker is not the high-risk one

Here is the finding that surprises almost everyone. In the Gandini meta-analysis of 57 studies, intermittent sun exposure carried a relative risk of 1.61 for melanoma, and a history of sunburn carried 2.03. Chronic sun exposure carried 0.95 — statistically indistinguishable from no effect, and if anything slightly protective.^[2] A roofer with forty years of daily UV on his forearms is not, on that basis alone, at elevated melanoma risk. The office worker who burns twice a summer on holiday is.

The mechanism is thought to be adaptation. Continuously exposed skin thickens its stratum corneum and maintains constitutive melanin, which blunts the DNA damage per unit of UV. Skin that stays pale for eleven months and then takes 8 standard erythema doses in one afternoon has no such defence. This is why the calculator above asks about blistering burns and sunbed use separately from cumulative outdoor time, and why cumulative outdoor time feeds only the basal and squamous cell score. If you want to model the burn side of the equation directly, our UV index calculator converts an index reading and your skin type into unprotected minutes before erythema begins.

Sunbeds fall firmly on the intermittent side. Pooled across 27 studies, ever having used one raised melanoma risk by 20%; first use before age 35 raised it by 59%.^[3] The age threshold matters more than the dose, which is why the calculator asks when you started rather than how many sessions you logged.

Mole count outweighs skin type

Most people assume pale skin is the dominant melanoma risk factor. It is not even close to the biggest one. Fitzpatrick type I versus type IV gives a relative risk of 2.09. Carrying more than 100 moles gives 6.89 — more than three times the effect.^[1] The nevus count is the single most powerful phenotypic predictor in the literature, and it scales smoothly rather than in steps:

Counting moles across a whole body is tedious and people give up halfway. Use the arm shortcut instead. A King's College London study of 3,694 twins found that more than 11 moles on the right arm predicted a whole-body count above 100, and 7 moles on the right forearm carried a nine-fold likelihood of more than 50 in total.^[9] Counting one arm takes ninety seconds and it is the highest-value ninety seconds in this entire assessment.

Why a skin cancer risk calculator should not multiply every factor

Take the published relative risks at face value and a red-haired, heavily freckled, blue-eyed Fitzpatrick type I gets 3.64 × 2.10 × 1.47 × 2.09, or 23-fold, from pigmentation alone. That number is nonsense, and the reason is obvious once stated: red hair, freckling, blue eyes and burn-prone skin are not four independent findings. They are four readings of the same underlying MC1R variant biology. Each meta-analytic relative risk was estimated against a general population that already contained the other three traits, so multiplying them double-counts the same signal three times over.

This calculator handles it in two ways. Within the pigmentation group it takes the single strongest signal rather than the product, so our red-haired type I scores 3.64, not 23. Within the mole group, atypical count enters at its square root, because people with many atypical moles almost always have many ordinary ones too. Then the four group totals are multiplied and the product is raised to the power 0.8, a shrinkage that keeps combined estimates inside the range published cohort studies actually observe. Without that exponent, Dan's profile above would read 28.6-fold and imply a lifetime risk of 24%, which is territory reserved for genetically confirmed CDKN2A carriers, not for a man with a freckled back and one affected parent.

A test of whether the calibration is honest: set the inputs to a typical fair-skinned adult — type II skin, 15 to 40 moles, one or two lifetime blistering burns, no family history — and the estimated lifetime risk comes out at 2.5%, or 1 in 39. The American Cancer Society puts lifetime melanoma risk for white Americans at about 1 in 38.^[4] A risk model that cannot reproduce the population average for an average person is not worth reading.

What changes at five atypical moles?

Five is the number where the calculator stops caring about your other answers and pushes you into the Very High tier regardless. Five atypical nevi carry a relative risk of 6.36 on their own.^[1]At that count the clinical label changes too: five or more clinically atypical moles, in the presence of a high total count, is the working definition of atypical mole syndrome, and it moves you from "watch your skin" into structured surveillance.

An atypical mole is not a pre-cancer in the way an actinic keratosis is. Most never become anything. Their value is as a marker: they signal a melanocyte population that has already tolerated genomic instability, and the melanoma, when it comes, usually appears on clear skin rather than inside one of the atypical moles you were watching. That is precisely why total-body photography earns its cost in this group. You are not tracking the known moles. You are trying to notice the new one.

Add two or more first-degree relatives with melanoma to five atypical moles and genetic testing becomes a reasonable conversation. CDKN2A mutations account for roughly 40% of high-density melanoma families, and carriers face lifetime risks in the range of 60% to 90% depending on the ambient UV where they live. No self-assessment tool can substitute for that referral.

Melanoma and keratinocyte cancers run on different engines

"Skin cancer" is at least three diseases with different arithmetic, which is why this tool reports two scores instead of one. Basal cell and squamous cell carcinoma — together, keratinocyte carcinomas — are overwhelmingly the common ones. An analysis of Medicare data estimated 5.4 million keratinocyte carcinomas treated in 3.3 million Americans in a single year, against roughly 100,000 invasive melanomas.^[5] They are fifty times more common and account for a small fraction of skin cancer deaths.

The transplant row is the one that changes clinical practice. A kidney recipient on tacrolimus does not have a slightly elevated skin cancer risk; they have a squamous cell risk up to two orders of magnitude above baseline, concentrated on the head and hands, and it compounds every year they stay on the drug. That is why ticking the immunosuppression box in the calculator jumps the recommended review interval to three to six months rather than annually.

Age behaves differently across the two as well. Melanoma incidence rises with age but is already meaningful in the thirties — it is one of the more common cancers in young adults. Keratinocyte carcinoma is close to an age-dose curve: the model above weights a 70-year-old at five times a 45-year-old for basal and squamous cell risk, and only marginally higher for melanoma. If you are interested in how the same cumulative-exposure logic shapes other conditions, our biological age calculator applies a comparable approach across organ systems.

The screening argument nobody has won

In 2023 the US Preventive Services Task Force reviewed the evidence for routine visual skin cancer screening in asymptomatic adults and issued an I statement: insufficient evidence to weigh benefits against harms.^[6]Dermatology bodies disagree, and both positions are defensible. Screening catches thin melanomas, and thinness is nearly everything — five-year relative survival is 99.6% for localised disease and 35.1% once it has spread to distant sites.^[7] But population-wide visual screening also finds a large number of indolent lesions, and no randomised trial has yet shown a mortality benefit.

The argument is unresolved for the general population. It is not unresolved for the top tier. Nobody disputes that a person with a prior melanoma, five atypical moles, or a functioning transplant belongs in surveillance. That is the real use of a risk multiplier: not to decide whether screening works in the abstract, but to work out which side of the evidence gap you personally sit on. If your number came back under 2, the Task Force statement is genuinely about you. Above 5, it is not.

What to actually do with a high number

Sunscreen earns its place here on trial evidence, not on plausibility. In the Nambour trial in Queensland, adults randomised to daily broad-spectrum sunscreen had 11 new melanomas over ten years of follow-up against 22 in the discretionary-use group, and invasive melanomas fell by 73%.^[8] That is one of the few primary-prevention results in oncology with a randomised design behind it. Daily, not beach-day, was the intervention.

Three habits do most of the remaining work. Self-examine monthly with a hand mirror, because the male back and the female posterior calf are the two most common melanoma sites and both are places you cannot see unaided. Photograph anything you are unsure about with a coin in frame for scale, then re-shoot in eight weeks — change over that interval is far more informative than any single snapshot. And treat the ugly duckling rule as a higher-priority signal than ABCDE: most of your moles resemble each other, and the outlier is the one worth showing someone, even if it breaks none of the five letters.

One last honest caveat about what a self-assessment cannot see. Acral and mucosal melanomas — on the soles, under the nails, on the palms — are largely independent of UV and of every phenotype input in this model. They are the melanomas that most often occur in people with Fitzpatrick type V and VI skin, who this calculator will place firmly in the Low tier and who therefore have the worst stage-at-diagnosis statistics of any group. A low number here is a statement about your UV-driven risk. It is not permission to ignore a dark streak under a toenail. For a wider view of modifiable risk across cancer types, the cancer risk calculator covers smoking, alcohol, weight and screening intervals, and the health risk calculator pulls several of those threads into one profile.

References

1. Gandini S, et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer. 2005;41(1):28–44. PubMed
2. Gandini S, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer. 2005;41(1):45–60. PubMed
3. Boniol M, et al. Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis. BMJ. 2012;345:e4757. PubMed
4. American Cancer Society. Key Statistics for Melanoma Skin Cancer. cancer.org
5. Rogers HW, et al. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the US population, 2012. JAMA Dermatol. 2015;151(10):1081–1086. PubMed
6. US Preventive Services Task Force. Screening for Skin Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2023;329(15):1290–1295. USPSTF
7. National Cancer Institute. SEER Cancer Stat Facts: Melanoma of the Skin. seer.cancer.gov
8. Green AC, et al. Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol. 2011;29(3):257–263. PubMed
9. Ribero S, et al. Prediction of high naevus count in a healthy UK population to estimate melanoma risk. Br J Dermatol. 2016;174(2):312–318. PubMed

Frequently Asked Questions